Metrogyl 200mg Tablet (Metronidazole 200mg)

Description

Metrogyl 200mg Tablet (Metronidazole 200mg) — Complete Clinical and Patient Information Guide

Product Overview

Metrogyl 200mg Tablet (Metronidazole 200mg) contains Metronidazole 200mg as its active pharmaceutical ingredient, belonging to the 5-nitroimidazole antibiotic and antiprotozoal agent — oral formulation. It is clinically indicated for anaerobic bacterial infections, protozoal infections (Giardia, Entamoeba, Trichomonas), H. pylori eradication (in combination), bacterial vaginosis. This comprehensive guide has been developed in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines to provide accurate, evidence-based information for patients and healthcare professionals.

Metrogyl 200mg provides the lower-dose option for infections requiring reduced dosing, for maintenance treatment, or for patients sensitive to higher metronidazole doses.

Understanding Metrogyl 200mg and Its Active Ingredient

Metronidazole 200mg is the pharmacologically active compound in Metrogyl 200mg. The drug class to which it belongs — 5-nitroimidazole antibiotic and antiprotozoal agent — oral formulation — has a well-established clinical evidence base developed across decades of research, regulatory review, and real-world clinical use. Understanding the mechanism of action, appropriate therapeutic use, necessary monitoring, and safety considerations of this medication is essential for achieving optimal clinical outcomes while protecting patient safety.

This product should only be used under appropriate medical supervision. For medications classified as YMYL (conditions where improper use carries significant health risk), professional medical guidance before initiating, modifying, or stopping therapy is not optional — it is a fundamental patient safety requirement. Patients are encouraged to maintain open, honest communication with their prescribing physician and pharmacist about all aspects of their treatment.

Mechanism of Action

Metronidazole is a 5-nitroimidazole antibiotic and antiprotozoal agent with a unique mechanism of bactericidal and antiprotozoal action. In anaerobic bacteria and protozoa, metronidazole undergoes reductive activation by low-redox-potential electron transport proteins (including ferredoxin and flavodoxin): the nitro group is reduced to form short-lived, highly reactive nitro radical anions that cause DNA strand breakage, disruption of nucleic acid synthesis, and ultimately bacterial or protozoal cell death. This mechanism is specific to organisms with anaerobic electron transport pathways — aerobic bacteria and human cells lack the reductive capacity to activate metronidazole, accounting for its selectivity for anaerobic bacteria and protozoa. Clinically, metronidazole provides effective treatment for: anaerobic bacterial infections (Bacteroides, Clostridium, Fusobacterium species); protozoal infections (Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica); Helicobacter pylori eradication (in combination); and rosacea (topical gel formulation — through anti-inflammatory rather than antibacterial mechanisms at the therapeutic concentrations achieved).

Understanding how this medication works at the molecular and cellular level helps explain the clinical requirements for optimal use: why specific timing, administration conditions, monitoring tests, contraindications, and drug interactions exist. Healthcare providers apply this mechanistic understanding to individualise therapy, anticipate drug interactions, counsel patients on what to expect, and monitor for treatment response and toxicity.

Clinical Indications

Metrogyl 200mg Tablet (Metronidazole 200mg) is clinically indicated for:

• Primary indication: anaerobic bacterial infections, protozoal infections (Giardia, Entamoeba, Trichomonas), H. pylori eradication (in combination), bacterial vaginosis
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of this specific medication for the individual patient. Self-diagnosis and self-treatment with prescription medications carries significant and potentially serious health risks.
• Treatment goals and monitoring: The prescribing physician establishes clear therapeutic objectives and a monitoring plan appropriate to the specific indication and the patient’s individual risk profile.

Dosage and Administration

For anaerobic infections: 200mg every 8 hours. For H. pylori eradication: 400mg or 500mg twice daily with a PPI and clarithromycin or amoxicillin for 7–14 days. For Giardia/Trichomonas: dose regimen as prescribed. Always take with food to reduce GI side effects. Avoid alcohol during and for 48 hours after treatment (disulfiram-like reaction).

Adherence to the prescribed dosing regimen is critical for therapeutic success and patient safety. Patients uncertain about their dosing schedule should contact their prescribing physician or pharmacist before making any changes. Never alter doses or stop therapy without medical advice, particularly for medications (such as systemic retinoids, alcohol dependence therapies, and corticosteroids) where abrupt changes can have significant consequences.

Who Should Use Metrogyl 200mg

Metrogyl 200mg is indicated for adult patients (and where specified, adolescent patients) who have been diagnosed by a qualified healthcare professional with the conditions listed in the indications section, and for whom this medication has been determined appropriate following assessment of individual benefits and risks. Patients should have no absolute contraindications and should be able to comply with any required monitoring or safety programme requirements.

Contraindications — Who Should Not Use Metrogyl 200mg

Hypersensitivity to metronidazole, other nitroimidazoles, or excipients. First trimester of pregnancy (avoid where possible — teratogenicity risk, particularly with high systemic doses). Not for use in CNS disease or epilepsy (reduced seizure threshold). Blood dyscrasias.

Before starting Metrogyl 200mg, patients must provide their prescribing physician with a complete medical history, including all current medications (prescription and over-the-counter), known allergies, and relevant personal and family medical history. Conditions that appear unrelated to the treatment indication may significantly affect prescribing decisions for drugs with complex safety profiles.

Drug Interactions

Alcohol: disulfiram-like reaction (oral metronidazole) — avoid all alcohol during and for 48 hours after oral treatment (severe flushing, tachycardia, nausea, vomiting). Warfarin: potentiation of anticoagulant effect — monitor INR closely. Lithium: increased plasma levels and toxicity risk. Ciclosporin: possible increased ciclosporin levels. Phenytoin/phenobarbital: accelerated metronidazole metabolism. Fluorouracil: reduced clearance (oncology setting). Disulfiram: avoid concurrent use.

Drug interactions can be clinically significant and potentially dangerous. A complete medication review by a qualified pharmacist or physician is essential before starting Metrogyl 200mg. Many interactions can be effectively managed through dose adjustment, temporal separation of doses, or alternative drug selection — but only when proactively identified. Patients should never add new medications (including herbal supplements and over-the-counter products) without checking for interactions with Metrogyl 200mg.

Adverse Effects and Side Effects

Oral: very common — metallic taste, nausea, vomiting, diarrhoea, and headache. Common — dizziness, darkened urine (harmless metabolite). Uncommon — peripheral neuropathy with prolonged use (paraesthesia — monitor and discontinue if develops). Rare — seizures at high doses, leucopenia, hepatotoxicity, encephalopathy (typically with prolonged high-dose therapy or significant renal failure).

Side effects vary in frequency, severity, and clinical significance. Patients should be educated before starting treatment about which side effects to expect and manage (expected retinisation with retinoids, mucocutaneous dryness with isotretinoin) versus which require prompt medical attention (signs of disulfiram-ethanol reaction, symptoms of pseudotumour cerebri, signs of hepatotoxicity). A proactive approach to side-effect education significantly improves treatment adherence and patient safety.

Special Population Considerations

Renal impairment: accumulation of metronidazole metabolites may occur in severe renal impairment — dose reduction or monitoring required. Hepatic impairment: reduce dose significantly in severe hepatic failure. Pregnancy (oral): avoid in first trimester if possible; use in second/third trimester only when clearly necessary. Topical metronidazole has negligible systemic absorption and is considered relatively safe in pregnancy.

Storage and Handling

Store Metrogyl 200mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat sources, and moisture. Keep in the original manufacturer’s packaging until required. Secure out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush down drains or discard in household waste, as pharmaceutical waste poses environmental hazards.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children and pets. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Never double-dose. Consult your prescriber if uncertain about how to manage a missed dose in your specific regimen.

Q: Why must I avoid alcohol with metronidazole?
A: Oral metronidazole inhibits acetaldehyde dehydrogenase — the enzyme that metabolises the toxic alcohol metabolite acetaldehyde. When alcohol is consumed concurrently, acetaldehyde accumulates, causing the disulfiram-like reaction: severe flushing, headache, tachycardia, nausea, and vomiting. Avoid all alcohol (including alcohol-containing medicines, mouthwash, and food cooked in wine) during treatment and for 48 hours after the last dose.

Q: How does metronidazole treat rosacea if it’s an antibiotic?
A: For rosacea, topical metronidazole works primarily through anti-inflammatory mechanisms rather than direct antibacterial activity. At the concentrations achieved in topical gel, it inhibits neutrophil-generated reactive oxygen species, reduces inflammatory mediator production, and suppresses the cutaneous inflammatory response that produces papules, pustules, and erythema in rosacea — independent of any significant antibacterial effect.

Clinical Evidence and Quality Standards

The active ingredient in Metrogyl 200mg has been evaluated in randomised controlled trials, meta-analyses, and extensive post-marketing surveillance studies supporting its use in the approved indications. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms, reflecting a high level of clinical confidence in its efficacy and safety profile when used appropriately.

Metrogyl 200mg is manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities. GMP certification ensures consistent product quality, identity, strength, purity, and safety across all manufactured batches. Patients should only obtain prescription medications from licensed pharmacies with a valid prescription to ensure they receive authentic, properly stored, regulatory-compliant products.

Evidence Base and Clinical Guidelines

The active ingredient(s) in this product have been evaluated in randomised controlled trials, systematic reviews, and extensive real-world clinical experience. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), WHO Model Formulary, and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms. The level of clinical confidence reflected in guideline recommendations is commensurate with the quality and consistency of supporting clinical evidence accumulated over years of research and practice.

Evidence-based prescribing requires matching the right treatment to the right patient at the right dose for the right duration — a principle that applies with particular importance to prescription dermatological and addiction medicine agents. Healthcare providers are encouraged to consult current approved prescribing information in their jurisdiction, as recommendations evolve with accumulating evidence.

Patient Education and Adherence

Treatment outcomes with this medication are significantly influenced by patient understanding and consistent adherence. Key patient education points include:

• Realistic expectations: Most acne treatments require 8–12 weeks of consistent use before full benefit is apparent. Premature discontinuation based on perceived lack of early response is the most common cause of inadequate acne treatment outcomes. For addiction medicine treatments, sustained engagement over 12–24 months produces far better outcomes than short-term pharmacotherapy.
• Consistency: Irregular use of topical dermatological products significantly reduces their efficacy. Topical retinoids applied only on lesion-by-lesion basis rather than across the entire acne-prone area underperform compared to whole-region daily application. For oral addiction medicines, daily dosing maintains therapeutic plasma levels essential for consistent pharmacological benefit.
• Side-effect management: Many side effects of dermatological medications — retinoid-induced dryness, initial acne flare, GI effects from antibiotics — are predictable, manageable, and temporary. Proactive counselling and supportive care prevent unnecessary treatment discontinuation due to manageable adverse effects that would otherwise resolve with continued treatment.
• Complementary measures: Non-pharmacological measures — sun protection, gentle skincare, dietary modifications, stress management, psychological support — significantly enhance the outcomes of both dermatological and addiction medicine pharmacotherapy.

Responsible Medication Use

Prescription medications should be obtained exclusively from licensed pharmacies with a valid prescription from a registered healthcare provider. Purchasing prescription medications from unlicensed online sources carries substantial risk of receiving counterfeit, substandard, incorrectly labelled, or contaminated products. Counterfeit dermatological medications have been associated with serious skin reactions, while counterfeit addiction medicine products may contain incorrect or dangerous substances. Patient safety demands obtaining medications through legitimate, regulated supply chains.

All unused or expired medications should be returned to a licensed pharmacy for safe disposal. Pharmaceutical waste poses environmental risks when flushed or discarded in household waste, and proper disposal prevents accidental access by children or others for whom the medication was not intended.

Important Medical Disclaimer

This product information page is provided for general educational purposes only, developed in accordance with YMYL (Your Money Your Life) content standards. The information presented draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician, dermatologist, addiction medicine specialist, or pharmacist. Drug therapy decisions must be individualised based on the complete clinical picture, comorbidities, and concurrent medications of each patient. Self-diagnosis and self-treatment of conditions managed by prescription medications can be dangerous and may lead to delayed diagnosis of serious underlying conditions, inappropriate drug use, or preventable adverse events. Always consult a qualified healthcare professional before starting, changing, or stopping this or any medication.